The retromer complex is a highly conserved multi-protein assembly that mediates the retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane. In the central nervous system, retromer dysfunction has emerged as a convergent pathogenic mechanism across multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [FTD](/diseases/ftd). [@mcgough2017]
The retromer plays a critical role in regulating the trafficking of [APP](/genes/app), [BACE1](/proteins/bace1-protein), sortilin, SorLA/SORL1, and neurotransmitter receptors — all proteins whose mislocalization contributes to neurodegeneration. [@seaman2013]
Reduced levels of retromer components, particularly VPS35 and VPS26, are found in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/cortex) of AD patients, while the VPS35 D620N mutation causes autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) — making the retromer both a disease biomarker and a therapeutic target. [@zhang2014]
The mammalian retromer core consists of a heterotrimer of vacuolar protein sorting (VPS) proteins:
The retromer complex is a highly conserved multi-protein assembly that mediates the retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane. In the central nervous system, retromer dysfunction has emerged as a convergent pathogenic mechanism across multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and [FTD](/diseases/ftd). [@mcgough2017]
The retromer plays a critical role in regulating the trafficking of [APP](/genes/app), [BACE1](/proteins/bace1-protein), sortilin, SorLA/SORL1, and neurotransmitter receptors — all proteins whose mislocalization contributes to neurodegeneration. [@seaman2013]
Reduced levels of retromer components, particularly VPS35 and VPS26, are found in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/cortex) of AD patients, while the VPS35 D620N mutation causes autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) — making the retromer both a disease biomarker and a therapeutic target. [@zhang2014]
The mammalian retromer core consists of a heterotrimer of vacuolar protein sorting (VPS) proteins:
| Subunit | Size | Function |
|---------|------|----------|
| VPS35 | 92 kDa | Central scaffold; directly binds cargo sorting receptors (SorLA, sortilin, CI-MPR) and recruits VPS26/VPS29 |
| VPS26 (A or B) | 38 kDa | Binds the N-terminal domain of VPS35; recognizes cargo via aromatic-hydrophobic sorting motifs |
| VPS29 | 21 kDa | Binds the C-terminal domain of VPS35; serves as a regulatory platform for retromer-associated proteins |
VPS35 forms an elongated alpha-helical solenoid that bridges VPS26 (at its N-terminus) and VPS29 (at its C-terminus). Mammalian VPS26 has two paralogues — VPS26A and VPS26B — which form distinct retromer complexes with partially overlapping but non-identical cargo specificity.
The cargo-recognition trimer works in concert with:
The retromer retrieves transmembrane cargo from the limiting membrane of maturing endosomes before they fuse with lysosomes. Key neuronal cargoes include:
The retromer also mediates direct recycling from endosomes to the plasma membrane, particularly important for:
The retromer regulates [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) through trafficking of ATG9A, the only multi-spanning transmembrane protein in the core autophagy machinery. Retromer dysfunction mislocalizes ATG9A, impairing autophagosome formation and compromising clearance of protein aggregates — directly linking retromer deficiency to the [protein aggregation](/mechanisms/protein-aggregation) seen in neurodegeneration.
Postmortem studies consistently demonstrate reduced levels of VPS35 and VPS26 in the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/entorhinal-cortex) of AD patients. This reduction occurs early in disease — detectable at Braak stage III-IV — suggesting that retromer dysfunction precedes widespread tau pathology and neuronal loss. [@small2015]
Retromer dysfunction prolongs the co-residence of [APP](/genes/app) and [BACE1](/proteins/bace1-protein) in acidic endosomal compartments — the primary site of amyloidogenic [APP](/genes/app) cleavage. When retromer fails to retrieve [APP](/genes/app), it remains in endosomes where BACE1 cleaves it to produce amyloid-beta, particularly the more aggregation-prone Aβ42. [@muhammad2018]
SORL1 (encoding SorLA) is a confirmed AD risk gene identified through GWAS. SorLA acts as a "gatekeeper" that shunts [APP](/genes/app) away from endosomal BACE1 cleavage. Retromer-mediated recycling of SorLA is essential for maintaining this protective function — reduced retromer directly impairs SorLA recycling, creating a vicious cycle of increasing amyloid-beta production. [@mishra2022] [@knupp2020] [@jensen2023]
SORL1 variants are associated with increased AD risk, and the interaction between SORL1 and retromer dysfunction creates a compounded vulnerability. [@lane2010]
One of the earliest neuropathological features in AD — detectable decades before symptom onset in [Down syndrome](/diseases/down-syndrome-alzheimers) patients — is endosomal enlargement in neurons. Retromer dysfunction is a primary driver of this phenotype, as impaired cargo retrieval causes endosomal swelling and disrupted intracellular trafficking.
Retromer stabilization in AD models reduces tau phosphorylation independently of amyloid precursor protein processing, suggesting that retromer dysfunction may contribute to tau pathology through distinct pathways. [@young2018]
In 2011, the VPS35 D620N missense mutation was identified as a cause of autosomal dominant late-onset [Parkinson's disease](/diseases/parkinsons-disease) (PARK17) — making VPS35 the first endosomal trafficking gene directly linked to PD. [@vilariño2011] [@zimprich2011]
The D620N mutation impairs retromer function through multiple mechanisms:
Retromer stabilization with the compound 2a (a bis-guanylhydrazone) rescued endosomal sorting, attenuated locomotion impairment, and increased motor neuron survival in ALS mouse models, demonstrating retromer dysfunction as a tractable target in ALS. [@bhatt2020]
Retromer dysfunction impairs sorting of [progranulin](/proteins/progranulin) (the product of the GRN gene, a major FTD risk gene), potentially contributing to the lysosomal dysfunction seen in GRN-FTD. [@herrero2021]
The most promising therapeutic approach is pharmacological chaperone-mediated retromer stabilization — small molecules that bind the VPS35-VPS29 interface to increase retromer complex stability and function:
| Compound | Class | Mechanism | Status |
|----------|-------|-----------|--------|
| R55 | Thiophene thiourea | Binds VPS35-VPS29 interface; increases retromer levels; reduces APP-BACE1 co-localization | Preclinical — reduces amyloid-beta, restores LTP, normalizes synaptic gene expression in AD mice [@bhatt2025] |
| Compound 2a | Bis-guanylhydrazone | Binds VPS35-VPS29; stabilizes retromer; bioavailable | Preclinical — neuroprotective in ALS mouse model [@mcgough2013] |
| RT-011 | — | Retromer stabilizer; increases VPS35 protein levels | Preclinical |
A 2025 study demonstrated that R55 treatment in an AD mouse model rescued synaptic dysfunction, restored endosomal trafficking, reduced amyloid-beta pathology, and normalized the expression of key synaptic genes (Gria1, Grip1, semaphorin/plexin pathway), providing strong preclinical evidence for retromer stabilization as a disease-modifying strategy. [@bhatt2025] [@curtis2023]
The pharmacological chaperone approach was first validated in 2014 with small molecule retromer stabilizers that reduced amyloidogenic APP processing in cell and mouse models. [@mecus2014] Subsequent studies extended these findings to human stem cell models of AD. [@young2018]
AAV-mediated overexpression of VPS35 has been explored as a gene therapy strategy for PD. In VPS35+/- mice, VPS35 restoration prevents dopaminergic neurodegeneration and normalizes alpha-synuclein levels.
A 2024 review discusses the progress in developing retromer-targeting therapeutics, highlighting the challenges of targeting a non-enzymatic scaffold protein and the promise of pharmacological stabilization approaches. [@wu2024] The field has advanced from proof-of-concept in cellular models to demonstrated efficacy in multiple animal models of AD, PD, and ALS.
The following diagram shows the key molecular relationships involving Retromer Complex discovered through SciDEX knowledge graph analysis: